

Title (en)

SOLID ORAL PHARMACEUTICAL COMPOSITIONS OF DABIGATRAN ETEXILATE

Title (de)

FESTE ORALE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN VON DABIGATRANETEXILAT

Title (fr)

COMPOSITIONS PHARMACEUTIQUES ORALES SOLIDES D'ÉTÉXILATE DE DABIGATRAN

Publication

EP 3621599 A2 20200318 (EN)

Application

EP 18811674 A 20180510

Priority

- TR 201706848 A 20170510
- TR 2018050220 W 20180510

Abstract (en)

[origin: WO2019004979A2] The present invention relates to solid oral pharmaceutical compositions, comprising dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof.

IPC 8 full level

A61K 9/48 (2006.01); **A61K 9/16** (2006.01); **A61K 9/50** (2006.01); **A61K 31/4439** (2006.01)

CPC (source: EA EP)

A61K 9/1611 (2013.01 - EA EP); **A61K 9/1652** (2013.01 - EA EP); **A61K 9/4808** (2013.01 - EP); **A61K 9/4858** (2013.01 - EA EP); **A61K 9/5015** (2013.01 - EA EP); **A61K 9/5031** (2013.01 - EA EP); **A61K 9/5047** (2013.01 - EA EP); **A61K 9/5084** (2013.01 - EP); **A61K 31/4439** (2013.01 - EA EP)

Citation (search report)

See references of WO 2019004979A2

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

WO 2019004979 A2 20190103; **WO 2019004979 A3 20190411**; AU 2018293361 A1 20200102; AU 2018293361 B2 20210916; BR 112019023781 A2 20200602; CO 2019013649 A2 20200515; EA 201992644 A1 20200407; EP 3621599 A2 20200318; EP 3634388 A2 20200415; NZ 759901 A 20211224; TR 201706848 A2 20181121; TR 201806309 A2 20181121

DOCDB simple family (application)

TR 2018050220 W 20180510; AU 2018293361 A 20180510; BR 112019023781 A 20180510; CO 2019013649 A 20191203; EA 201992644 A 20180510; EP 18811674 A 20180510; EP 18811675 A 20180510; NZ 75990118 A 20180510; TR 201706848 A 20170510; TR 201806309 A 20180504